Stroke Center, University of California, San Diego, La Jolla, CA 92093-9127, USA.
Neurology. 2011 Oct 4;77(14):1330-7. doi: 10.1212/WNL.0b013e3182315234. Epub 2011 Sep 28.
To qualitatively and quantitatively assess the association of prehypertension with incident stroke through a meta-analysis of prospective cohort studies.
We searched Medline, Embase, the Cochrane Library, and bibliographies of retrieved articles. Prospective cohort studies were included if they reported multivariate-adjusted relative risks (RRs) and corresponding 95%confidence intervals (CI) of stroke with respect to baseline prehypertension.
Twelve studies with 518,520 participants were included. Prehypertension was associated with risk of stroke (RR 1.55, 95% CI 1.35-1.79; p < 0.001). Seven studies further distinguished a low prehypertensive population (systolic blood pressure [SBP] 120-129 mm Hg or diastolic blood pressure [DBP] 80-84 mm Hg) and a high prehypertensive population (SBP 130-139 mm Hg or DBP 85-89 mm Hg). Among persons with lower-range prehypertension, stroke risk was not significantly increased (RR 1.22, 0.95-1.57). However, for persons with higher values within the prehypertensive range, stroke risk was substantially increased (RR 1.79, 95% CI 1.49-2.16).
Prehypertension is associated with a higher risk of incident stroke. This risk is largely driven by higher values within the prehypertensive range and is especially relevant in nonelderly persons. Randomized trials to evaluate the efficacy of blood pressure reduction in persons with this designation are warranted.
通过对前瞻性队列研究的荟萃分析,定性和定量评估高血压前期与中风事件的相关性。
我们检索了 Medline、Embase、Cochrane 图书馆和检索文章的参考文献。如果前瞻性队列研究报告了基线高血压前期与中风相关的多变量校正后的相对风险(RR)和相应的 95%置信区间(CI),则将其纳入研究。
纳入了 12 项研究,共 518520 名参与者。高血压前期与中风风险相关(RR 1.55,95%CI 1.35-1.79;p < 0.001)。进一步区分了低高血压前期人群(收缩压[SBP] 120-129mmHg 或舒张压[DBP] 80-84mmHg)和高高血压前期人群(SBP 130-139mmHg 或 DBP 85-89mmHg)。在低高血压前期人群中,中风风险没有显著增加(RR 1.22,0.95-1.57)。然而,对于高血压前期范围内较高值的人群,中风风险显著增加(RR 1.79,95%CI 1.49-2.16)。
高血压前期与中风事件发生的风险增加相关。这种风险主要由高血压前期范围内较高的值驱动,尤其是在非老年人群中更为显著。需要进行随机试验来评估在高血压前期人群中降低血压的疗效。